These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 16449001

  • 1. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
    Garbino J, Markham L, Matulionyte R, Rives V, Lew D.
    Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
    [Abstract] [Full Text] [Related]

  • 2. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P, Thamlikitkul V.
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [Abstract] [Full Text] [Related]

  • 3. Retrospective evaluation of amphotericin B deoxycholate toxicity in a single centre series of haematopoietic stem cell transplantation recipients.
    Annaloro C, Olivares C, Usardi P, Onida F, Della Volpe A, Tagliaferri E, Deliliers GL.
    J Antimicrob Chemother; 2009 Mar; 63(3):625-6. PubMed ID: 19158110
    [No Abstract] [Full Text] [Related]

  • 4. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, Baden LR.
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [Abstract] [Full Text] [Related]

  • 5. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, Krobot KJ, Gerth WC, Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators.
    Clin Infect Dis; 2006 Aug 15; 43(4):e29-38. PubMed ID: 16838223
    [Abstract] [Full Text] [Related]

  • 6. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
    Morello E, Pagani L, Coser P, Cavattoni I, Cortelazzo S, Casini M, Billio A, Rossi G.
    Bone Marrow Transplant; 2011 Jan 15; 46(1):132-6. PubMed ID: 20383205
    [Abstract] [Full Text] [Related]

  • 7. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
    Altmannsberger P, Holler E, Andreesen R, Krause SW.
    J Antimicrob Chemother; 2007 Jul 15; 60(1):180-2. PubMed ID: 17537868
    [No Abstract] [Full Text] [Related]

  • 8. [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
    Quinteros A R, Fica C A, Abusada A N, Muñoz C L, Novoa M C, Gallardo A C.
    Rev Chilena Infectol; 2010 Feb 15; 27(1):25-33. PubMed ID: 20140311
    [Abstract] [Full Text] [Related]

  • 9. Reduction of nephrotoxicity associated with amphotericin B deoxycholate.
    Johnson JR.
    Clin Infect Dis; 2004 Jan 15; 38(2):303; author reply 306-7. PubMed ID: 14699469
    [No Abstract] [Full Text] [Related]

  • 10. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?
    Schneemann M, Bachli EB.
    Clin Infect Dis; 2004 Jan 15; 38(2):303-4; author reply 306-7. PubMed ID: 14699468
    [No Abstract] [Full Text] [Related]

  • 11. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K.
    Clin Infect Dis; 2009 Feb 01; 48(3):265-73. PubMed ID: 19115967
    [Abstract] [Full Text] [Related]

  • 12. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
    Oto OA, Paydas S, Disel U, Yavuz S, Seydaoglu G.
    Mycoses; 2007 Mar 01; 50(2):135-9. PubMed ID: 17305778
    [Abstract] [Full Text] [Related]

  • 13. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.
    Drew RH, Dodds Ashley E, Benjamin DK, Duane Davis R, Palmer SM, Perfect JR.
    Transplantation; 2004 Jan 27; 77(2):232-7. PubMed ID: 14742987
    [Abstract] [Full Text] [Related]

  • 14. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
    Drew R.
    Int J Antimicrob Agents; 2006 Jun 27; 27 Suppl 1():36-44. PubMed ID: 16713192
    [Abstract] [Full Text] [Related]

  • 15. Amphotericin B deoxycholate: time to retire our old standard?
    Gallagher JC.
    Expert Rev Anti Infect Ther; 2005 Jun 27; 3(3):313-6. PubMed ID: 15954845
    [No Abstract] [Full Text] [Related]

  • 16. Are there risk factors for acute renal failure in adult patients using deoxycholate amphotericin B?
    Tuon FF, Koenig F, Jacometto D, Rocha JL.
    Rev Iberoam Micol; 2013 Jan 03; 30(1):21-4. PubMed ID: 22995903
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL, Chaudhari P, Natoli JL, Taylor RJ, Nathanson BH, Horn DL.
    Diagn Microbiol Infect Dis; 2013 Jul 03; 76(3):361-7. PubMed ID: 23774005
    [Abstract] [Full Text] [Related]

  • 20. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
    Rothenbühler C, Held U, Manz MG, Schanz U, Gerber B.
    Hematol Oncol; 2018 Apr 03; 36(2):471-480. PubMed ID: 29431860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.